Member Info for Ivyspivey

Crumbs/TF
If a pharma Company has agreed to manu then to me that means they are either prepared to manu themselves or subcontract to a CMO.
Vax producing facilities are absolutely at a premium and virtually none in UK so additional govt facilities planned.
The need for huge scale up is paramount therefore you are talking 10s of millions of £ and a lead time of 6-9 months so they would have to repurpose existing facilities to get it done sooner.
The disruption to current Vax production would be immense and I know from my time at Sanofi how complex this is and no Leading pharma would agree to this commitment unless it was made at the highest level.
This is not an agreement to use govt facilities planned for the future this is an agreement with a commercial pharma Company who would not be interested in manufacturing it without a deal to commercialise.

Don’t forget most of the leading Vax players will already be producing their normal products.
I am well aware of the time and expense it takes to repurpose Vax facilities or add additional capacity so they don’t just agree to manufacture this Vax unless they have done a massive amount of DD at Senior level so well done SCLP but we must have this confirmed.

Morning All
TF I think that bit is the most important part of the article as it means that the approach is validated and there are only a handful of leading pharma with the ability to manufacture Vax so likes of Merck,Sanofi etc.
If true this is huge news and a major step forward and if we get an RNS confirming this tomorrow this will absolutely surge.
ATB

Did not fully answer your question.
I do think there is a lot of potential beyond Covid 19 but we need more news on who the RTO May involve to know more detail.
Covid 19 is an all consuming angle ATM so many are not looking beyond that.

Mr Nation,I think if Iclaprim had been Approved or even pre Approval the Covid 19 effect would have been very timely here.However given the very early stage of the LaMellar tie up and fact Iclaprim is not Approved means there is little scope for direct Covid 19 involvement.The LaMellar technology does seem to have good potential vs some of the associated effects of Covid 19 like ARDS and particularly In vulnerable people who we know are more likely to require intensive care.It may be that Covid 19 becomes a big focus for a RTO and of course this could really drive the Level of interest.However I have to say there is still a long way to go to develop these treatments but I am aware of other Covid plays that equally are a long way off but people seem to think they have the answer.

Thanks PR,
I know there are LTH here who have held throughout and hoping for a huge recovery play. The real damage was done on the CRL and after trying to retrieve what I could I decided to exit after the AGM when I felt GL had misled SH.
I have primarily come back for a short term trade but happy to try and provide some historical perspective.I reserve the right as all of us to buy more/ sell/ hold based on news and sentiment but please make your own decision.

This is the RNS I referred to earlier.
Maybe Covance just accepted MTFB had no money and not worth pursuing or perhaps they were in some way complicit In trial design that resulted in the FDA issuing the CRL requesting more data.
There was speculation on the board at that time whether Covance had erred in not following up the trial patients who had elevated liver enzyme levels In sufficient numbers.

https://www.lse.co.uk/rns/MTFB/settlement-agreement-w74yh9jdvubpgry.html

This is what CEO of LaMellar said when RNS was announced.

Dr. Alex McLean, Chief Executive Officer of Lamellar Biomedical, said: "CF is a key area of interest for Lamellar. We are delighted to announce this partnership with Motif Bio, which will evaluate the antibiotic potentiation properties of our LAMELLASOME™ technology in combination with iclaprim. This collaboration augments our own work in this orphan indication, which is focused on a novel nucleic acid-based therapeutic, as we strive to develop a range of highly effective treatment options for patients with CF."

So if use of Iclaprim with this technology leads to synergy then I can see good potential for this combination in respiratory conditions.
I am not suggesting at all this will be a Covid play as all work so far is pre clinical but suggest it may be a change of emphasis for MTFB.
A year ago MTFB were focusing purely on responding to the CRL and one of options to satisfy FDA was to do do HABP trial.But of course they did not have any money and was not made clear to SH exactly what was required by FDA.
However I did notice a change of emphasis at the 2019 AGM moving more towards respiratory rather than ABSSSI.
I put this down to just to answer the CRL if a big trial was needed then made no sense to repeat an ABSSSI one so may as well do a HABP/VABP as 21st Century Cures Act would be supportive of this approach.
In addition you have the LaMellar tie up and of course work in the aerosol version with US army.
I sold out of MTFB soon after AGM so lost interest in the story but this possible repositioning of Iclaprim into a respiratory setting especially given the FDA Sept minutes and the other news means that the strategic direction may have changed.
The reason why this may be important is that seeking a RTO and setting up a new Company positioned as an a infectious disease outfit socialising in respiratory conditions may be indicative of who may be involved.
As I say these are purely my own musings and I have not had contact with GL for a year so absolutely no input there at all.

C7 I hope you and all others are safe and well.
It is now 3 times you have referred to me as somehow wanting to deride posters here.You cannot be further from the truth but your mind is made up so no point in trying to convince you otherwise.
Imo some on here simply don’t want any balanced debate/ see any contrary views and seek to “ demonise” any that have the temerity to argue or ask for an update.
My decision to trade some is seen by you as an evil act and only after I have tried to undermine the SP.
Why would I do that when my core holding Is still 5x the size of my trade.
Also your trade which you gleefully told everyone put Xmas food on the table and you emulated in this last week is seen by you as a positive Vote of confidence in SCLP.I call that rank hypocrisy.
As for listening to advice from Nana about investing.
He criticised me for selling 250k here at 8p and buying AVCT when it dropped to 15p.
Well that £20k would now be worth £190k if I had held all the way whereas if I had followed his advice and not sold here it would be worth £17k.
So hope you can understand why I make my own decisions and please in future just leave me out if your posts and wind your neck in.
ATB

The last 3 large sells have all been delayed trades but the 1M was a delayed historical.

Moljen,
Hope you are not off to “Greta”Green(sic) this w/ end as Scottish lockdown still evident lol.
Did anyone notice the 400k sell at 6.52 yesterday?

Again Looed great effort and many thanks

Octopus increasing holding

https://www.investegate.co.uk/fusion-antibodies--fab-/rns/holding-s--in-company/202005151649091120N/

Afternoon Moljen,
Very much agree with the tenor of your post.I am in a number of other pharma/diagnostic tests and the general level of knowledge is very poor but these are the people making the investment decisions .Being helpful in terms of explaining things concisely and clearly Is very much appreciated but you highlight a clear danger of over elaborating on the science and also of course it is not just the knowledge but the way it is communicated that can readily affect sentiment.
It is that sentiment which is clearly lacking here but in fairness I did buy some today for a small trade.
ATB and we wait to see the news flow in the coming weeks

HinLooed,
The date is 25/3/19 but I don’t know if thst relates to original setting up of new Company so would possibly fit in with predicting the transfer of the asset as liquidation would be predictable
The opportunity With Hope off board arose a month or so later.
There us also the date of November 2019 and some mortgage from bank of Georgia.
But I really am clutching at straws trying to make some sense of what it may mean.

Morning,
Yes very apt as this has been mentioned before by the Adapter Group in terms of using Aptamers not only in diagnostic tests but as therapeutics.
I have always iresumed the therapeutics they refer to are viral neutralising actions via the spike protein.
Essentially this is what Avct have annnounced this morning.

OK Bermuda different experiences lol.
I always look on the SP as the ultimate driver of performance as to most Companies it is the most important KOI in reflecting BoD performance and major SH return.

PS My experience of options is that they are not normally conditional just set at a particular Level to reflect performance and SH alignment.

Agree Bermuda,
Did RG and LD not sell some shares on one occasion( think it may have been before I bought in here) and my understanding is they have never bought any directly so these must have been options.
As I said if they could have sold them in 2015 surely they would have exercised them as it would have been a nice earner but obviously they did not meet criteria

Evening Bermuda,
Hope you are well and safe.
Makes total sense to have options based on KPIs like sake of Company as surely they would have exercised those options in 2015 as the SP was comfortably at many multiples of where we are now.